Neuronetics Competitors
| STIM Stock | USD 1.30 0.03 2.36% |
Correlation: Neuronetics vs Genfit SA Overview
Good diversification
The correlation between STIM and GNFT is -0.17, which Macroaxis classifies as Good diversification for the selected horizon. Used correctly, the chart helps investors judge whether adding the second position genuinely diversifies the first.
Moving together with Neuronetics Stock
Moving against Neuronetics Stock
The mean reversion principle applied to Neuronetics' suggests that neither prolonged outperformance nor underperformance is permanent. Investors exploit this by positioning against extremes in price relative to fundamental value.
Neuronetics Competition Correlation Matrix
Correlation analysis between Neuronetics and its competitors helps investors understand whether diversification is real or only superficial inside the same peer group. This matrix is most informative when investors want to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Neuronetics Stock performing well and Neuronetics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Neuronetics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PRE | 4.20 | 0.78 | 0.16 | 0.45 | 4.16 | 13.33 | 27.11 | |||
| NYXH | 2.78 | -0.55 | 0.00 | -0.35 | 0.00 | 5.07 | 21.88 | |||
| ATLN | 6.42 | 1.84 | 0.28 | 0.73 | 5.38 | 18.21 | 64.87 | |||
| OABI | 2.23 | -0.07 | 0.00 | -0.11 | 0.00 | 5.29 | 16.11 | |||
| CATX | 5.22 | 1.59 | 0.27 | 1.03 | 4.96 | 11.81 | 77.44 | |||
| OSUR | 2.19 | 0.37 | 0.14 | 0.28 | 2.34 | 5.98 | 16.03 | |||
| PROF | 3.11 | -0.12 | 0.00 | -0.12 | 0.00 | 5.94 | 38.55 | |||
| CDXS | 4.23 | -0.07 | 0.00 | -0.30 | 0.00 | 10.20 | 24.68 | |||
| SGMO | 4.51 | 0.01 | 0.00 | -0.04 | 0.00 | 7.89 | 73.25 | |||
| GNFT | 3.17 | 0.64 | 0.14 | 11.15 | 3.86 | 7.34 | 25.18 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Neuronetics financial statement analysis. It represents the amount of money remaining after all of Neuronetics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Neuronetics and related stocks such as Prenetics Global, Nyxoah, and Atlantic International Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRE | 142.3 M | 1.1 B | 1.1 B | 664 M | 1.1 B | 104.4 M | -20.1 M | -20.1 M | -20.1 M | -20.1 M | -1.9 M | -174 M | -190.5 M | -62.7 M | -46.3 M | -58.3 M | -55.4 M |
| NYXH | -10.4 M | -10.4 M | -10.4 M | -10.4 M | -10.4 M | -10.4 M | -10.4 M | -10.4 M | -9.1 M | -9.5 M | -12.2 M | -27.6 M | -31.2 M | -43.2 M | -59.2 M | -53.3 M | -50.6 M |
| ATLN | -1.4 M | -1.4 M | -1.4 M | -1.4 M | -1.4 M | -1.4 M | -1.4 M | -1.7 M | -2.9 M | -2.5 M | -1 M | -40.8 M | -3.2 M | -15.3 M | -135.5 M | -121.9 M | -115.8 M |
| OABI | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -17.6 M | -27 M | -22.3 M | -50.6 M | -62 M | -64.8 M | -61.5 M |
| CATX | -437.6 K | -2.8 M | -3.5 M | -3.9 M | -6 M | -3.7 M | -4.7 M | -6.2 M | -4.8 M | -3.3 M | -3.2 M | -7.3 M | -14.7 M | -46.5 M | -79.3 M | -71.4 M | -67.8 M |
| OSUR | -2.6 M | -8.8 M | -15.1 M | -11.2 M | -4.6 M | 8.2 M | 19.7 M | 30.9 M | 20.4 M | 16.7 M | -14.9 M | -23 M | -17.1 M | 53.7 M | -19.5 M | -68.7 M | -65.3 M |
| PROF | -8.2 M | -8.2 M | -8.2 M | -8.2 M | -8.2 M | -11.8 M | -12.1 M | -15 M | -15.2 M | -15.2 M | -21.6 M | -30.7 M | -28.7 M | -28.6 M | -26.5 M | 42.3 M | 44.4 M |
| CDXS | -18.7 M | -16.6 M | -30.9 M | -41.3 M | -19.1 M | -7.6 M | -8.6 M | -23 M | -10.9 M | -11.9 M | -24 M | -21.3 M | -33.6 M | -76.2 M | -65.3 M | -44 M | -46.2 M |
| SGMO | -308 K | -35.8 M | -22.3 M | -26.6 M | -26.4 M | -40.7 M | -71.7 M | -54.6 M | -68.3 M | -75.8 M | -121.1 M | -178.3 M | -192.3 M | -257.8 M | -97.9 M | -88.1 M | -83.7 M |
Neuronetics Competitive Analysis
How does Neuronetics measure up against Prenetics Global, Nyxoah, and Atlantic International? The financials tell a nuanced story. Neuronetics operates at a 88.7 M scale with 74.9 M flowing through the income statement. Neuronetics currently operates at a -34.27% net margin with return on equity at -218.99%, reflecting headwinds in the current cycle. Prenetics Global converts shareholder equity more efficiently at -31.79% versus Neuronetics at -218.99%. Neuronetics pulls in 74.9 M in revenue while the other reports 4.5 M. Atlantic International holds the larger valuation at 297.0 M versus 88.7 M.| Better Than Average | Worse Than Peers | View Performance Chart |
Peer Performance Charts
How to Analyze Neuronetics Against Peers
Neuronetics' peer analysis compares Neuronetics with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Neuronetics trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Neuronetics leads or lags and what catalysts could close or widen the gap.